Keywords: B-Raf inhibitors; Mitogen-activated protein kinase inhibitor; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-Programmed cell death-1; Metastatic melanoma; Cutaneous adverse event; Inhibidores de BRAF; Inhibidores de MEK; Anti-CTLA4; Anti-PD1; Mela